Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 5Healthy Participants 5Breast Neoplasms 5Prostatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Venous Thromboembolism 2Solid Tumor, Adult 2Neoplasm Metastasis 2Healthy Volunteers 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cardiovascular Diseases 2cMET-dysregulated Advanced Solid Tumors 1Venous Thrombosis 1TP53 Y220C Mutation 1Stroke 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Pulmonary Embolism 1Prostatic Neoplasms, Castration-Resistant 1Precancerous Conditions 1Peripheral Nervous System Diseases 1Pain 1Ovarian Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Liver Cirrhosis 1Leiomyosarcoma 1

Interventions

capmatinib 2Rosuvastatin Calcium 1Midazolam 1Digoxin 1Caffeine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × cMET-dysregulated Advanced Solid Tumors × Rosuvastatin Calcium × Clear all
NCT02626234 2020-12-10

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Novartis

Phase 1 Completed
32 enrolled
Other solid neoplasm

cMET-dysregulated Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡